
Opinion|Videos|June 1, 2024
The Evolving Treatment Landscape in BCG-Unresponsive NMIBC
Bladder cancer experts discuss the evolving treatment landscape in BCG-unresponsive NMIBC and give an overview of TAR-200, an emerging therapy.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves first-line Zenflow system for the treatment of BPH
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5



















